The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Predictive value of KRAS mutation status in metastatic colorectal cancer (mCRC) patients treated with capecitabine and bevacizumab (CAP-B) maintenance treatment vs observation in the phase III CAIRO3 study.
 
Kaitlyn K.H. Goey
No Relationships to Disclose
 
Sjoerd G. Elias
No Relationships to Disclose
 
Harm van Tinteren
No Relationships to Disclose
 
Miangela M. Lacle
No Relationships to Disclose
 
Stefan M. Willems
Honoraria - Pfizer; Roche/Genentech
Consulting or Advisory Role - Pfizer; Roche
 
Wendy W.J. de Leng
No Relationships to Disclose
 
Eric Strengman
No Relationships to Disclose
 
Celien Vreuls
No Relationships to Disclose
 
Geert-Jan Creemers
No Relationships to Disclose
 
Ankie Van Der Velden
No Relationships to Disclose
 
Cornelis J. A. Punt
Consulting or Advisory Role - Amgen; Bayer; Merck Serono; Roche
 
Miriam Koopman
Consulting or Advisory Role - Amgen; Bayer; Merck; Roche
Speakers' Bureau - Bayer
Research Funding - Bayer; Merck; Roche
Travel, Accommodations, Expenses - Amgen; Bayer; Roche